AzTrials
AzTrials

AKI in Diabetic KetoacidosisNCT05508490

Prevalence of Acute Kidney Injury in Patients With Diabetic Ketoacidosis

An observational study of AKI in Diabetic Ketoacidosis, run by Assiut University.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

prevalence of acute kidney injury in patients with diabetic ketoacidosis Read more about this study

Who is it for?
Ages 1 year to 18 years
Conditions the study is for
AKI in Diabetic Ketoacidosis
What is being tested?
renal chemistry, serum electrolyte,
How many people
100 participants
Where
No sites listed yet
Study dates
1 Jan 2023to 30 Apr 2024
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 year to 18 years
  • All sexes
  • Child, Adult

Study population: All included children were subjected to 1. detailed medical history including demographic data (name, age, and sex), age of onset, family history of type 1 diabetes mellitus (DM1), and duration of the disease, previous attacks of DKA. 2. clinical examination with particular emphasis on assessment of anthropometric measures (weight and height), evaluation of systolic and diastolic blood pressures, monitoring of urine output (UOP), and recording of complications (cerebral edema, sepsis, need for vasoactive drugs, need for respiratory support and mortality). 3. laboratory investigations including daily urine output, urea, creatinine, serum chloride level, Na, K and arterial blood gases (ABG) every third day and albumin/creatinine ratio (ACR) every week. Follow-up of blood urea and creatinine till normalization of kidney function or occurance of failure.

Who may be able to join

  • The inclusion criterion was children with DKA with an age range between 1 and 18 years

Who cannot join

  • The exclusion criteria were patients with septic shock, acute pancreatitis, and chronic kidney disease and patients who received fluid therapy before referral to our hospital

Trial locations and contacts

No sites are listed yet.

Ahmed Refaat, resident doctor contact

01012581156

ahmedrefaat1995227@gmail.com

About this study

prevalence of acute kidney injury in patients with diabetic ketoacidosis

Read the detailed description

Acute kidney injury (formerly known as acute renal failure) is a syndrome characterised by the rapid loss of the kidney's excretory function and is typically diagnosed by the accumulation of end products of nitrogen metabolism (urea and creatinine) or decreased urine output, or both.

  • Stages of kidney injury:
  1. Risk: 1.5 folds increase in serum creatinine and urine output less than 0.5 ml/kg/hr for 6 hours.
  2. Injury: two folds increase in serum creatinine and urine output less than 0.5 ml/kg/hr for 12 hours.
  3. Failure: three folds increase in serum creatinine and urine output less than 0.3 ml/kg/hr for 24 hours or anuria for 12 hours.
  4. Loss: complete loss of kidney function > 4 weeks
  5. End stage kidney disease: complete loss of kidney function > 3 months It is the clinical manifestation of several disorders that affect the kidney acutely. Acute kidney injury is common in hospital patients and very common in critically ill patients. In these patients, it is most often secondary to extrarenal events. How such events cause acute kidney injury is controversial. No specific therapies have emerged that can attenuate acute kidney injury or expedite recovery; thus, treatment is supportive. New diagnostic techniques (eg, renal biomarkers) might help with early diagnosis. Patients are given renal replacement therapy if acute kidney injury is severe and biochemical or volume-related, or if uraemic-toxaemia-related complications are of concern. If patients survive their illness and do not have premorbid chronic kidney disease, they typically recover to dialysis independence. However, evidence suggests that patients who have had acute kidney injury are at increased risk of subsequent chronic kidney disease. Children with diabetic ketoacidosis (DKA) are at significant risk for various degrees of dehydration and disruption of electrolyte balance due to osmotic diuresis [1]. As a consequence of chronic polyuria, progressive dehydration is common in patients with DKA [2]. Children are less likely to establish the compensatory process for dehydration than adults, making them more vulnerable to dehydration [3]. In patients with extreme volume loss, pre-renal acute kidney injury (AKI) is likely, and acute tubular necrosis can occur. As the rate of glomerular filtration decreases, there is insufficient kidney acid excretion, thereby aggravating metabolic acidosis [4]. Since metabolic acidosis normalization is one of the goals of DKA management [1], AKI can adversely affect recovery from metabolic acidosis for these patients. Besides, AKI is an independent risk factor for a prolonged hospital stay and increased mortality rates [5]. DKA is managed by volume resuscitation, insulin therapy, and correction of electrolyte imbalances [6]. Resuscitation using traditional saline in DKA patients can exacerbate electrolyte abnormalities, in particular the production of hyperchloremia [7, 8]. While an increase of evidence suggests that hyperchloremia is linked to an increased risk of morbidity and mortality, its effects in DKA are not well defined [9, 10]. Aim of study 1: to detect prevalence of acute kidney injury in pediatric patients with diabetic ketoacidosis and its impact as regard to;
  • duration of hospital stay.
  • Occurance of complications
  • response to treatment. 2: to detect the type of kidney injury in diabetic ketoacidosis wether it is renal or pre renl.

Type of study Observational Cross-Sectional study

Sample size Sample size will be determined through statistical analysis by Public health department

Patients and methods All included children were subjected to

  1. detailed medical history including demographic data (name, age, and sex), age of onset, family history of type 1 diabetes mellitus (DM1), and duration of the disease, previous attacks of DKA.
  2. clinical examination with particular emphasis on assessment of anthropometric measures (weight and height), evaluation of systolic and diastolic blood pressures, monitoring of urine output (UOP), and recording of complications (cerebral edema, sepsis, need for vasoactive drugs, need for respiratory support and mortality).
  3. laboratory investigations including daily urine output, urea, creatinine, serum chloride level, Na, K and arterial blood gases (ABG) every third day and albumin/creatinine ratio (ACR) every week.

Follow-up of blood urea and creatinine till normalization of kidney function or occurance of failure.

Being tested
renal chemistry, serum electrolyte,

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • renal chemistry, serum electrolyte,Diagnostic test

    detection of renal chemistry affection and electrolyte disturbance in diabetic ketoacidosis

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. prevalence of acute kidney injury in diabetic ketoacidosis

    detection of renal function affection and electrolyte disturbance in patients with diabetic ketoacidosis

    Measured: Baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Aug 2022
  2. Study start1 Jan 2023 (estimated)
  3. Primary completion30 Apr 2024 (estimated)
  4. Study completion30 Apr 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05508490
Sponsor's protocol ID
AKI in DKA
Status last verified
Aug 2022
First submitted
18 Aug 2022
Last updated
19 Aug 2022
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Yang EM, Lee HG, Oh KY, Kim CJ. Acute Kidney Injury in Pediatric Diabetic Ketoacidosis. Indian J Pediatr. 2021 Jun;88(6):568-573. doi: 10.1007/s12098-020-03549-9. Epub 2020 Nov 19.

    PubMed 33210207

Questions about this trial

What is this clinical trial studying?

An observational study of AKI in Diabetic Ketoacidosis, run by Assiut University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 19 Aug 2022. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Ahmed Refaat, resident doctor (01012581156, ahmedrefaat1995227@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

prevalence of acute kidney injury in diabetic ketoacidosis (time frame: Baseline). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05508490, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Aug 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in